Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8.9% | -13.9% | -5.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 60% | 59.9% | 62.5% | 74.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -70.2% | -120.8% | -152% | -115.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -74.1% | -98.4% | -148.8% | -120.2% |
| EPS Diluted | -2.22 | -11.14 | -25.9 | -23.89 |
| % Growth | 80.1% | 57% | -8.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |